| 1 |
Youn J, Stehlik J, Wilk A, et al. Temporal trends of de novo malignancy development after heart transplantation [J]. J Am Coll Cardiol, 2018, 71(1): 40-49.
|
| 2 |
Serraino D, Piselli P, Busnach G, et al. Risk of cancer following immunosuppression in organ transplant recipients and in HIV-positive individuals in southern Europe [J]. Eur J Cancer, 2007, 43(14): 2117-2123.
|
| 3 |
Rianldi M, Pellegrini C, Armini D, et al. Neoplastic disease after heart transplantation: single center experience [J]. Eur J Cardiothorac Surg, 2001, 19(5): 696-701.
|
| 4 |
Blasco L, Parameshwar J, Vuylsteke A, et al. Anaesthesia for noncardiac surgery in the heart transplant recipient [J]. Curr Opin Anaesthesiol, 2009, 22(1): 109-113.
|
| 5 |
Chih S, Chong A, Mielniczuk L, et al. Allograft vasculopathy: The Achilles' heel of heart transplantation [J]. J Am Coll Cardiol, 2016, 68(1): 80-91.
|
| 6 |
Diujvestijn A, Derhaag J, Vriesman P, et al. Complement activation by anti-endothelial cell antibodies in MHC-mismatched and MHC-matched heart allograft rejection: anti-MHC-, but not anti non-MHC alloantibodies are effective in complement activation [J]. Transpl Int, 2000, 13(5): 363-371.
|
| 7 |
Wehner J, Morrell C, Reynolds T, et al. Antibody and complement in transplant vasculopathy [J]. Circ Res, 2007, 100(2): 191-203.
|
| 8 |
Costanzo M, Dipchand A, Sarling R, et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients [J]. J Heart Lung Transplant, 2010, 29(8): 914-956.
|